Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Get Free Report) were down 6.8% during trading on Monday after an insider sold shares in the company. The company traded as low as $322.44 and ...

Analysts at B. Riley raised their Q1 2025 earnings per share estimates for Madrigal Pharmaceuticals in a research report issued on Thursday, February 27th. B. Riley analyst M. Mamtani now expects that ...

Madrigal Pharmaceuticals' Rezdiffra had a strong launch with $103.3M in Q4 sales and solid liquidity. See why I have a ...

BofA raised the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $239 from $154 and keeps an Underperform rating on ...

Benzinga's options scanner spotted 9 options trades for Madrigal Pharmaceuticals. This is not a typical pattern. The sentiment among these major traders is split, with 44% bullish and 44% bearish.

Three months ago, in its third-quarter report, Madrigal pointed out that it achieved a key goal early by gaining 80% coverage ...

B. Riley upgraded Madrigal Pharmaceuticals (MDGL) to Buy from Neutral with a price target of $422, up from $236. The firm notes the erosion of ...

CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) has announced its financial results for 2024, marking a ...

Citi raised the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $469 from $378 and keeps a Buy rating on the shares post the Q4 ...

But the harsh reality is that very many loss making companies burn through all their cash and go bankrupt. So, the natural question for Madrigal Pharmaceuticals (NASDAQ:MDGL) shareholders is whether ...